Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium blocks COX enzymes, lowering prostaglandin production and reducing inflammation and pain. Orphenadrine citrate acts centrally as an anticholinergic and NMDA‑receptor antagonist, producing muscle relaxation and additional analgesia, complementing the NSAID effect.

The dosage of Neodolpasse is determined by the prescribing clinician based on the patient’s condition, severity of pain, and clinical response. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety of Neodolpasse in pregnancy or lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk, and only under direct medical supervision.

To request Neodolpasse, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neodolpasse uniquely combines diclofenac, a potent COX inhibitor, with orphenadrine, a central muscle relaxant. Compared with separate NSAID and muscle‑relaxant agents, the fixed‑dose IV formulation offers coordinated pharmacokinetics and may simplify dosing in acute care settings.

Neodolpasse should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Neodolpasse is administered intravenously by a qualified healthcare professional. The injection is given as an infusion or bolus according to the prescriber’s instructions, typically in a clinical setting such as a hospital or surgical centre.

Serious risks include severe allergic reactions (anaphylaxis, angioedema), hepatotoxicity, renal impairment, and significant bleeding, especially when combined with other NSAIDs or anticoagulants. Patients should be monitored closely for these events.

Neodolpasse is contraindicated in patients with known hypersensitivity to diclofenac, orphenadrine, or any component of the formulation. It should also be avoided in individuals with active gastrointestinal ulceration, severe renal or hepatic impairment, and in those taking certain interacting medications without medical supervision.